HPV Vaccine May Cut 30% of Oropharyngeal Cancers Beyond 90% Cervical Protection
Updated
Updated · News18 · Jun 3
HPV Vaccine May Cut 30% of Oropharyngeal Cancers Beyond 90% Cervical Protection
3 articles · Updated · News18 · Jun 3
Summary
New research suggests HPV vaccination could also lower the risk of HPV-related head and neck cancers, extending protection beyond its established role in preventing cervical cancer.
Around 30% of oropharyngeal cancers — affecting the middle throat, tonsils and base of the tongue — are now linked to HPV, making the virus a growing driver of these cancers.
The vaccine already prevents more than 90% of cervical cancers tied to HPV by blocking high-risk strains that can trigger cancer development.
Health guidance still centers on early prevention: two doses are typically given at ages 11 or 12, can start at 9, and catch-up shots are recommended through age 26.
Researchers say the findings strengthen the case for wider vaccination as oral cavity and pharyngeal cancers rise, even though tobacco remains the leading overall risk factor and heavy drinking also raises risk.
The HPV vaccine stops cancer, so why are mouth and throat cancer rates still rising in some groups?
With US health agencies giving conflicting advice, is one HPV vaccine dose now enough to prevent cancer?
Why is global coverage for a cancer-preventing vaccine still below 30%, far from the WHO's 90% goal?
HPV Vaccination: The Missed Opportunity to Prevent Tens of Thousands of Cancers in the U.S. Each Year
Overview
The HPV vaccine, approved in the United States in 2006, is widely recognized for reducing the risk of cervical cancer and has now been confirmed to prevent other HPV-related cancers, especially oropharyngeal cancer in men. Medical experts strongly agree on its preventative power, emphasizing that broader use could prevent tens of thousands of cancer cases each year. The vaccine works by stopping HPV infection, which can lead to cancers of the head, neck, and other areas. This consensus highlights the vaccine’s vital role in cancer prevention and the urgent need to increase vaccination rates, particularly among boys and young men.